Physician profile
Robert S Adams
NPI 1154305548
$445.77
in general payments reported to CMS, 2019-2025
12 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $416 · 2020: $12.79 · 2022: $16.83.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $203.13 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $56.03 | 2019 | |
| Sanofi-Aventis U.S. LLC | $38.38 | 2019 | |
| Sunovion Pharmaceuticals INC. | $34.16 | 2019 | |
| Genzyme Corporation | $22.32 | 2019 | |
| Phadia US INC. | $16.83 | 2022 | |
| Allergan, INC. | $13.14 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $13.10 | 2019 | |
| Pfizer INC. | $12.79 | 2020 | |
| Genentech USA, INC. | $12.42 | 2019 | |
| Abbvie INC. | $12.27 | 2019 | |
| Amarin Pharma, INC. | $11.20 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Adams listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.